OBJECTIVE: The objective of this study was to examine the use of gonadotrophin-releasing hormone agonist (GnRH-a) for luteal phase in a group of patients with thin endometrium (<or=7 mm) after IVF treatment. METHODS:One-hundred-and-twenty women were eligible for this study. Patients were randomly allocated into two groups: group A (n = 60) received triptorelin 0.1 mg on the day of ovum pickup (OPU), on the day of embryo transfer (ET) and three days thereafter, and group B (n = 60) received placebo. The primary outcomes were implantation and pregnancy rates. RESULTS: Although there was no significant difference in the number of good quality embryos transferred in both groups, the implantation and pregnancy rate were significantly higher in the GnRH-a - treated group compared with placebo controls. Furthermore, Estradiol (E(2)), progesterone (P) levels and endometrial thickness were significantly more elevated in patients who received GnRH-a for luteal phase support. CONCLUSIONS: The administration of GnRH-a at the time of OPU significantly improves the implantation and pregnancy rates in patients with thin endometrium (<or=7 mm).
RCT Entities:
OBJECTIVE: The objective of this study was to examine the use of gonadotrophin-releasing hormone agonist (GnRH-a) for luteal phase in a group of patients with thin endometrium (<or=7 mm) after IVF treatment. METHODS: One-hundred-and-twenty women were eligible for this study. Patients were randomly allocated into two groups: group A (n = 60) received triptorelin 0.1 mg on the day of ovum pickup (OPU), on the day of embryo transfer (ET) and three days thereafter, and group B (n = 60) received placebo. The primary outcomes were implantation and pregnancy rates. RESULTS: Although there was no significant difference in the number of good quality embryos transferred in both groups, the implantation and pregnancy rate were significantly higher in the GnRH-a - treated group compared with placebo controls. Furthermore, Estradiol (E(2)), progesterone (P) levels and endometrial thickness were significantly more elevated in patients who received GnRH-a for luteal phase support. CONCLUSIONS: The administration of GnRH-a at the time of OPU significantly improves the implantation and pregnancy rates in patients with thin endometrium (<or=7 mm).
Authors: Michelle van der Linden; Karen Buckingham; Cindy Farquhar; Jan A M Kremer; Mostafa Metwally Journal: Cochrane Database Syst Rev Date: 2015-07-07
Authors: João Batista A Oliveira; Ricardo Baruffi; Cláudia G Petersen; Ana L Mauri; Mario Cavagna; José G Franco Journal: Reprod Biol Endocrinol Date: 2010-09-08 Impact factor: 5.211
Authors: Robert K Hunter; Chris D Nevitt; Jeremy T Gaskins; Bradley B Keller; Henry C L Bohler; Amanda J LeBlanc Journal: PLoS One Date: 2015-12-14 Impact factor: 3.240